Waverley Weighs Its Options With High Costs, Thin Margins
Small Molecule Oncology Specialist Battered By Competition
Waverley is evaluating options for its generics as it looks likely to throw its all at the company’s lead product candidate in the hopes of luring a development partner or buyer.
You may also be interested in...
Following patent expiry on 24 May, Alimta ANDA products have reached the US market, eating into a product that generated more than $1.2bn in sales last year.
Canadian generic oncology specialist Waverley Pharma has cross-listed on the Frankfurt Stock Exchange.
In an acquisition said by both US-based companies to be highly complementary, Azurity Pharmaceuticals has taken control of Slayback Pharma for an undisclosed fee.